|
|
Post by markado on May 22, 2019 8:57:45 GMT -5
We all know the game, by now. The shorts, no matter where from will try to suppress the SP between now and through Dec to ensure the failure of the $1.60 options and the injection if another $40M into MNKD. The only counters to this are increased sales of Afrezza, confirmed agreements and formulary changes with large insurers, completed international deals with sales, and milestones from other TS partnerships, new or existing. We need completed events and achieved metrics, regularly. We need to be above $1.60...preferably at $2.00+ by Dec, to insulate from an intentional take down. Let's not play rinse and repeat, right into their hands. Let's make the case unequivocal and get these impediments out if the way!
|
|
|
|
Post by markado on May 22, 2019 17:34:35 GMT -5
We all know the game, by now. The shorts, no matter where from will try to suppress the SP between now and through Dec to ensure the failure of the $1.60 options and the injection if another $40M into MNKD. The only counters to this are increased sales of Afrezza, confirmed agreements and formulary changes with large insurers, completed international deals with sales, and milestones from other TS partnerships, new or existing. We need completed events and achieved metrics, regularly. We need to be above $1.60...preferably at $2.00+ by Dec, to insulate from an intentional take down. Let's not play rinse and repeat, right into their hands. Let's make the case unequivocal and get these impediments out if the way! Let me add to this, increase awareness and visibility to Afrezza, it's differentiating factors and its spokespersons. Hope is not a strategy. We often have to assume that everything we will try will fail, so we have the inherent need to double down with numerous but highly measurable marketing and promotion activities. To date, I give MNKD a C- in this department, and that's generous, given the degree of over investment in Marketing and Sales salaries, and the reported resumes. All at MNKD need training in lateral thinking, guerilla marketing and modern media tactics. Otherwise, we're just wasting time and money. |
|
|
|
Post by bizinvestor on May 25, 2019 4:58:25 GMT -5
Speaking of building faster, please tell me if my line of thinking here is off. Nrx has been averaging approx. 200 per week for the past two years and approx. 300 refills. If each rx is refilled every 3 months, if we retained those Nrx that would equate to 1900 refills each week. Advertising has had little effect on Rx. Instead of wasting 9 million on a very confusing tv ad why not have our sales reps reach out to each new patient and make sure they know how to dose Af. and help them with insurance problems. If we were at 1900 Rx at this point our share price would be 9-10 a share and we would be close to cash flow positive. Everyone of these patients that gets a Rx has already cleared our biggest hurdles of Drs prescribing and getting it into patients hands. Why not focus more time and money on retention of patients and less on these ineffective TV commercials. Seems to me if you were to do a better social media blitz it would cost much less and could be more focused. This would be a fraction of the advertising cost and more time and money could be spent on retention. Am I missing something here? Is it even possible for Mannkind to get new patient info to contact them and help them get accustomed to Afrezza? Do we know why our retention rate is so low? I keep hearing because it is not covered by insurance however if that were the case, wouldn't have all those people who left for that reason jump at the DTC promotion. Did all these people who stopped even know that was an option?
With such a great product I don't understand how this is not selling better. I have never witnessed such passionate responses for a product like this from those who use it and have such a hard time making a success for shareholders. Most of the time if you invest early in a product that is life changing you hit one of those once in a lifetime investments. I made my first purchase 7 years ago and can't believe how badly this drug has failed to this point. It's not over yet but boy has it been a crappy journey to this point. Hoping for a positive change in direction soon!!
|
|
|
|
Post by markado on May 25, 2019 6:31:17 GMT -5
bizinvestor - I agree. The other concern that I have, is that I've seen many good to great biotech co's get over taken by macroeconomic events, only to then use them as excuses for their floundering performance. A constant push forward means your working through the kinks and impediments in your business model; you're working around your competitors; and, you're gaining momentum to push through external event obstacles. And, that's if 60% of your efforts go your way. We're too early in the post-Snafui process (even 2+ years later) for MNKD execs to even begin to feel comfortable. They need burrs under their saddles, fire under their feet and in their bellies. I'm just not sensing as much passion, and I think that's because they're finding the work harder than anticipated. We'll, that's why they get paid "the big bucks," and why options and share awards should be super valuable. They just have to keep making it "so".
|
|
|
|
Post by hellodolly on May 25, 2019 9:21:10 GMT -5
Speaking of building faster, please tell me if my line of thinking here is off. Nrx has been averaging approx. 200 per week for the past two years and approx. 300 refills. If each rx is refilled every 3 months, if we retained those Nrx that would equate to 1900 refills each week. Advertising has had little effect on Rx. Instead of wasting 9 million on a very confusing tv ad why not have our sales reps reach out to each new patient and make sure they know how to dose Af. and help them with insurance problems. If we were at 1900 Rx at this point our share price would be 9-10 a share and we would be close to cash flow positive. Everyone of these patients that gets a Rx has already cleared our biggest hurdles of Drs prescribing and getting it into patients hands. Why not focus more time and money on retention of patients and less on these ineffective TV commercials. Seems to me if you were to do a better social media blitz it would cost much less and could be more focused. This would be a fraction of the advertising cost and more time and money could be spent on retention. Am I missing something here? Is it even possible for Mannkind to get new patient info to contact them and help them get accustomed to Afrezza? Do we know why our retention rate is so low? I keep hearing because it is not covered by insurance however if that were the case, wouldn't have all those people who left for that reason jump at the DTC promotion. Did all these people who stopped even know that was an option? With such a great product I don't understand how this is not selling better. I have never witnessed such passionate responses for a product like this from those who use it and have such a hard time making a success for shareholders. Most of the time if you invest early in a product that is life changing you hit one of those once in a lifetime investments. I made my first purchase 7 years ago and can't believe how badly this drug has failed to this point. It's not over yet but boy has it been a crappy journey to this point. Hoping for a positive change in direction soon!! I was reading on FB yesterday a user who who took a photograph of his refrigerator stuffed with his Afrezza. He was looking for a way to maximize the space because of how much Afrezza takes up after every 3 month refill. If new prescriptions are getting written every month and we've plateau'd at 270-300 after two years, are these new scripts essentially written for early users with just some trickledown to new scripts? Also, we have to subtract those who have not refilled after a year for whatever reason. If so, the cause for the equilibrium or plateau? Are new users being added at the same rate we are losing patients, say because of insurance, cost, etc? With all of the excitement on FB and Twitter, etc. I'm not reading about people jumping off the ship. Just the opposite, many are fighting to keep it...We have a long way to go before critical mass. Just can't put the finger on this Rx stabilizing. Earlgray puts out a great chart on trajectory of gross sales every five weeks or so. It's hard to reconcile the growth with flat numbers. What else is going on or, what variables am I missing from my thoughts? |
|
|
|
Post by sportsrancho on May 25, 2019 9:52:55 GMT -5
Most of the time they get one script per year with four 3 month refills.
I think many people do not know about the Afrezza Facebook page so they get on it and get off it because they don’t have the right dosing instructions, that’s why the Facebook page works so well. They have each other. They have Sam:-)
There’s a learning curve and without the doctors understanding it you’re got two ways to go... Vdex or the early adopters.
|
|
|
|
Post by travis1953 on May 25, 2019 10:56:41 GMT -5
Has anyone ever seen an actual sales rep presentation? What exactly do they say and/or do once they've got the physician cornered?
|
|
|
|
Post by mike0475 on May 25, 2019 13:40:01 GMT -5
Most of the time they get one script per year with four 3 month refills. I think many people do not know about the Afrezza Facebook page so they get on it and get off it because they don’t have the right dosing instructions, that’s why the Facebook page works so well. They have each other. They have Sam:-) There’s a learning curve and without the doctors understanding it you’re got two ways to go... Vdex or the early adopters. Problem w facebook is the age range of users. Sub 50yrs you make look to fb for help, might be even sub 47-48 or 45 I don’t have fb and I’m 43 Didn’t have MySpace either My is 47 and uses it My parents are early 70s. Don’t use it Blame me no grand kids... |
|
|
|
Post by mnkdfann on May 25, 2019 16:29:22 GMT -5
Instead of wasting 9 million on a very confusing tv ad why not have our sales reps reach out to each new patient and make sure they know how to dose Af. and help them with insurance problems. Do sales reps know the identities of individual patients? When someone fills a prescription, does the pharma actually get the patient's name? I imagined this information would be protected. |
|
|
|
Post by sportsrancho on May 25, 2019 17:23:01 GMT -5
Instead of wasting 9 million on a very confusing tv ad why not have our sales reps reach out to each new patient and make sure they know how to dose Af. and help them with insurance problems. Do sales reps know the identities of individual patients? When someone fills a prescription, does the pharma actually get the patient's name? I imagined this information would be protected. Yes they do. Me......@bhr01 laborer75 They aren’t titrating right or dosing correctly, it’s different when you have a MNKD long for a dad and you’re taking the drug. Or you went to Vdex and used their protocol. People get on it and get off it because they have don’t have guidance and the doctors aren’t informed. laborer.......@rooksleanne @bhr01 That's 100% accurate. My kid was supposed to meet up with Mannkind rep and his doctor to learn the correct way to use it. The rep finally called the house a week AFTER my kid was already using it. When the rep was told he was already using it, that rep didn't feel it important to meet up with him and his doctor. That rep missed a great opportunity to inform my son's doctor. This was the old Chicago rep. The new one must be just as shitty though judging by script numbers and retention rate. Management does not have this staff trained properly. Shit is all mixed up over there! ]And there’s just one more reason that we are trading at a pps of $1.17! Smh! To hear that some reps are STILL basically incompetent is unacceptable! Even after a painful reverse split on the most effective and efficient mealtime insulin known to man! That, combined with the lack of promotion through social media, it’s no wonder! However, I do realize that implementing a revolutionary new treatment into the mainstream market has its inherent challenges, but at the same time, why every T is not crossed and every I is not dotted by management is beyond me! That’s a simple and easy fix! I personally just don’t get it! And I, like many of you, am in deep! Come on management, carry on Alfred Mann’s brilliant legacy appropriately. He deserves it, PWD deserve it, we long term investors deserve it! Beyond Frustrating! Read more: mnkd.proboards.com/thread/6109/mnkd-on-stocktwits?page=27#ixzz5oygUzCFy |
|
|
|
Post by mnkdfann on May 25, 2019 18:19:18 GMT -5
Do sales reps know the identities of individual patients? When someone fills a prescription, does the pharma actually get the patient's name? I imagined this information would be protected. Yes they do. Me......@bhr01 laborer75 They aren’t titrating right or dosing correctly, it’s different when you have a MNKD long for a dad and you’re taking the drug. Or you went to Vdex and used their protocol. People get on it and get off it because they have don’t have guidance and the doctors aren’t informed. laborer.......@rooksleanne @bhr01 That's 100% accurate. My kid was supposed to meet up with Mannkind rep and his doctor to learn the correct way to use it. The rep finally called the house a week AFTER my kid was already using it. When the rep was told he was already using it, that rep didn't feel it important to meet up with him and his doctor. That rep missed a great opportunity to inform my son's doctor. This was the old Chicago rep. The new one must be just as shitty though judging by script numbers and retention rate. Management does not have this staff trained properly. Shit is all mixed up over there! If a doctor contacts a rep to work with a patient, or a rep contacts a doctor to offer assistance with any patients having trouble, or a patient contacts a doctor and asks the doc to set up a meeting with a rep, or a patient contacts a rep and asks they both meet with the doctor, those are all special cases. In all of those I can see how a rep would learn the patient's identity. I don't know the details of laborer's situation. Could it be one of those? But if a random patient fills a prescription does the pharmacy really relay that information to the local rep? Or do doctors automatically inform reps every time they prescribe that rep's product? Those are the cases I was wondering about. |
|
|
|
Post by nylefty on May 25, 2019 18:40:23 GMT -5
Most of the time they get one script per year with four 3 month refills. I think many people do not know about the Afrezza Facebook page so they get on it and get off it because they don’t have the right dosing instructions, that’s why the Facebook page works so well. They have each other. They have Sam:-) (clipped) Problem w facebook is the age range of users. Sub 50yrs you make look to fb for help, might be even sub 47-48 or 45 (clipped) The young people I know say that Facebook is for "older" people. I'm 85 and almost all of my 114 Facebook Friends are in their 50s, 60s, 70s, or 80s. |
|
|
|
Post by sportsrancho on May 25, 2019 19:31:35 GMT -5
Yes they do. Me......@bhr01 laborer75 They aren’t titrating right or dosing correctly, it’s different when you have a MNKD long for a dad and you’re taking the drug. Or you went to Vdex and used their protocol. People get on it and get off it because they have don’t have guidance and the doctors aren’t informed. laborer.......@rooksleanne @bhr01 That's 100% accurate. My kid was supposed to meet up with Mannkind rep and his doctor to learn the correct way to use it. The rep finally called the house a week AFTER my kid was already using it. When the rep was told he was already using it, that rep didn't feel it important to meet up with him and his doctor. That rep missed a great opportunity to inform my son's doctor. This was the old Chicago rep. The new one must be just as shitty though judging by script numbers and retention rate. Management does not have this staff trained properly. Shit is all mixed up over there! If a doctor contacts a rep to work with a patient, or a rep contacts a doctor to offer assistance with any patients having trouble, or a patient contacts a doctor and asks the doc to set up a meeting with a rep, or a patient contacts a rep and asks they both meet with the doctor, those are all special cases. In all of those I can see how a rep would learn the patient's identity. I don't know the details of laborer's situation. Could it be one of those? But if a random patient fills a prescription does the pharmacy really relay that information to the local rep? Or do doctors automatically inform reps every time they prescribe that rep's product? Those are the cases I was wondering about. No not the pharmacy. I believe the doctor contacts the rep to help with the patient. Because probably he doesn’t have any nurse practitioners that know how to do it. Let me ask him though and make sure. |
|
|
|
Post by helmut8056 on May 25, 2019 20:19:40 GMT -5
I turned 88 last month and have been invested nine yrs. in mankind big time and my prostate cancer has finally caught up with me. The good news is my mankind investment will not be a burden on my mind in a very short time.
|
|
|
|
Post by lifebreath on May 25, 2019 20:39:38 GMT -5
I turned 88 last month and have been invested nine yrs. in mankind big time and my prostate cancer has finally caught up with me. The good news is my mankind investment will not be a burden on my mind in a very short time. sorry Helmut |
|
